Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

SS-31 Research Guide: Cardiolipin, Mitochondria, and Elamipretide

SS-31 research centers on the mitochondrial membrane lipid cardiolipin. Follow the mechanism, a major clinical trial, and the precise meaning of elamipretide’s approval.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Literature names SS-31; elamipretide
Molecule class Synthetic tetrapeptide
Research focus Cardiolipin-associated mitochondrial membrane biology
Hero catalog sizes 10 mg and 50 mg
Material distinction Catalog research material is separate from the approved Forzinity medicine
Hero product SS-31

SS-31 is a synthetic tetrapeptide studied in mitochondrial biology and developed clinically under the name elamipretide. Its research story centers on cardiolipin, a lipid associated with the inner mitochondrial membrane. That focus makes it more specific than a general claim about “boosting mitochondria.”

Hero’s supplied export lists SS-31 in 10 mg and 50 mg formats. Understanding the literature requires separating three things: mechanistic experiments, disease-specific clinical findings, and the identity of the material actually being studied.

What SS-31 is: a membrane-focused research molecule

Birk and colleagues investigated SS-31 in work connecting the peptide with cardiolipin and mitochondrial responses to ischemic injury. Their 2013 paper examined interactions involving cardiolipin and cytochrome c, alongside experimental mitochondrial and kidney-injury measurements (Birk et al., 2013).

The lipid connection matters because mitochondria are organized systems. A change involving a membrane-associated interaction is a narrower research question than an assertion that all mitochondrial functions improve. Keep the proposed mechanism visible when choosing which endpoint to measure.

SS-31 also is distinct from the mitochondrial-derived peptide MOTS-c and the coenzyme NAD+. Their names may appear in the same search results, but that does not make them interchangeable. The separate MOTS-c guide and NAD+ guide address different molecules and experimental questions.

How cardiolipin research connects mechanism with measurement

The Birk study linked SS-31’s cardiolipin interaction with changes in cytochrome c-related behavior and mitochondrial function under the tested conditions. This provides a mechanistic rationale for further experiments. It does not establish that every mitochondrial disorder has the same response (Birk et al., 2013).

A useful study plan separates binding or interaction evidence from a downstream biological result. Does the experiment directly examine the proposed membrane interaction? Does it measure respiration, a tissue response, or another endpoint? Those observations can complement each other without being equivalent.

The comparison group is equally important. A baseline difference between samples and a treatment-associated change are different findings. Researchers should define which comparison addresses their question before interpreting a favorable-looking measurement as evidence for the whole proposed mechanism.

What the clinical evidence actually says

Karaa and colleagues reported the MMPOWER-3 randomized trial in people with primary mitochondrial myopathy. The study randomized 218 participants and assessed walking distance and fatigue as primary endpoints. It did not meet those primary endpoints (Karaa et al., 2023).

Source Setting What it contributes Key boundary
Birk et al., 2013 Mechanistic and preclinical work Cardiolipin-associated mitochondrial findings Experimental mechanisms are not broad clinical proof
Karaa et al., 2023 Primary mitochondrial myopathy trial Direct assessment of walking and fatigue endpoints The trial did not meet its primary endpoints
FDA, 2025 Forzinity accelerated approval A specific regulatory decision for Barth syndrome Applies to the approved medicine and defined indication

In September 2025, FDA granted accelerated approval to Forzinity, an elamipretide medicine, for Barth syndrome in patients weighing at least 30 kg. The agency described improved knee-extensor muscle strength as the basis reasonably likely to predict patient benefit and required a confirmatory trial (FDA, 2025).

These are different evidence settings. A decision in Barth syndrome does not turn an unsuccessful primary mitochondrial myopathy trial into a positive one. Nor does it establish efficacy for every condition described as mitochondrial.

Why an approved medicine and a research vial remain distinct

An approval is attached to a specific drug product, manufacturing controls, labeling, and indication. It does not transfer to any material sold under a related molecular name. Hero’s catalog SS-31 should therefore be described using its own research specifications rather than presented as Forzinity.

The same distinction applies when reading a clinical paper. The trial preparation and a laboratory sample need independent documentation. Shared naming alone cannot establish formulation equivalence, manufacturing equivalence, or suitability for the same purpose.

For a literature review, retain the actual endpoint and population beside each conclusion. “Mitochondrial research” is a topic, not one result. A cell experiment, a clinical trial, and a regulatory decision can all be relevant without answering the same question.

Laboratory planning for Hero SS-31

The 10 mg and 50 mg formats describe supplied catalog quantities. They do not establish final concentration, peptide content, or the exact salt and terminal specifications of a sample. Confirm those details against the intended method and matching lot documentation.

For mitochondrial assays, document the model, preparation history, and normalization approach. Decide whether the question requires isolated mitochondria, intact cells, or another system. A result in one preparation should not be assigned automatically to another.

Use validated preparation and storage conditions. Include controls that can distinguish a sample-associated response from effects of the vehicle or assay background. Identity verification helps define the test article, while suitable biological controls help interpret its response; neither substitutes for the other.

SS-31 research FAQ

Is SS-31 also called elamipretide?

Elamipretide is the name used in clinical development. When connecting a sample to a paper, compare the actual chemical and formulation specifications as well as the name.

Is Hero SS-31 the approved Forzinity medicine?

No. The catalog research material is separate from the approved drug product. The medicine’s approval does not establish the specifications or clinical suitability of a research vial.

Did MMPOWER-3 meet its primary endpoints?

No. The reported trial did not meet its primary walking-distance and fatigue endpoints in the studied primary mitochondrial myopathy population.

What SS-31 sizes does Hero list?

The supplied export lists 10 mg and 50 mg. Consult current product and lot documentation when matching material to a laboratory method.

SS-31. View catalog product

References

  1. Birk AV, et al. The Mitochondrial-Targeted Compound SS-31 Re-Energizes Ischemic Mitochondria by Interacting with Cardiolipin. J Am Soc Nephrol. 2013;24:1250-1261. Source.
  2. Karaa A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology 2023;101:e238-e252. Source.
  3. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. FDA News Release September 19, 2025; checked November 18, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack